Amgen helps back $32 mln Series B funding of Fortuna Fix

Laval, Québec-based regenerative medicine company Fortuna Fix Inc has raised about $32 million (US$25 million) in a Series B financing. The round was backed by the venture capital arm of U.S. biopharmaceutical company Amgen Inc, which joins other new and existing investors, including Macnguyen Family Office and Salamander Invest. Led by CEO and CSO Jan-Eric Ahlfors, Fortuna has developed technology platforms for treating neurodegenerative diseases and neurotrauma. It will use the funds raised for clinical trials in Parkinson's disease and spinal cord injury and to expand its automated robotic manufacturing capabilities.

CanadaNorth AmericaBriefs